Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
- Poster presentation highlights investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demons...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
- Poster presentation highlights investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demons...
Source route
Continue on news.abbvie.com
Leave the platform to read the original full article on the publisher site.
Source: AbbVie News
Scope: Industry
Related coverage
More related coverage
Exdensur (depemokimab) approved in China for the treatment of severe asthma
Exdensur is the first and only ultra-long-acting biologic in China for the treatment of severe asthm...
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
Submission supported by statistically significant and clinically meaningful functional cure rates in...
Sumitomo Pharma Submits Partial Change Application in Japan to Add Pediatric Dosage and Administration for LATUDA in Schizophrenia
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: To...
Shionogi Announces Corporate Reorganization and Personnel Reassignment (Effective April 1, 2026)
OSAKA, Japan, February 13, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO...